Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds B of A Securities Downgrades UBS Gr to Neutral

B of A Securities Downgrades UBS Gr to Neutral

B of A Securities analyst Alastair Ryan downgrades UBS Gr (NYSE:UBS) from Buy to Neutral.

byBenzinga Newsdesk

July 26, 2022

1 minute read

B of A Securities analyst Alastair Ryan downgrades UBS Gr (NYSE:UBS) from Buy to Neutral.

JPMorgan CEO Jamie Dimon Touches On Retirement Plans: ‘The Timetable Isn’t Five Years Anymore’

By Benzinga Neuro

May 20, 11:22 PM

Jamie Dimon, the CEO of JPMorgan Chase & Co, hinted at his retirement within the next five years. This revelation has left investors and analysts speculating about the future leadership of the bank.

JPM

Why Tilray Stock Is Trading Lower Tuesday

By Adam Eckert

April 11, 8:45 AM

Tilray Brands Inc (NASDAQ: TLRY) shares are trading lower Tuesday after the cannabis company reported fiscal third-quarter results and announced an acquisition of HEXO Corp (NASDAQ:

HEXO

News

Why Processa Pharmaceuticals (PCSA) Stock Is Skyrocketing

By Henry Khederian

January 19, 11:24 AM

Processa Pharmaceuticals shares are trading higher by 36.9% during Friday's session. The company announced plans to expand the development of Next Generation Capecitabine.

PCSA

Baird Maintains Outperform on Arrowhead Pharma, Lowers Price Target to $58

By Benzinga Newsdesk

February 7, 8:36 AM

Baird analyst Joel Beatty maintains Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and lowers the price target from $60 to $58.

ARWR

B of A Securities Downgrades UBS Gr to Neutral

Related Posts

JPMorgan CEO Jamie Dimon Touches On Retirement Plans: ‘The Timetable Isn’t Five Years Anymore’

Why Tilray Stock Is Trading Lower Tuesday

Why Processa Pharmaceuticals (PCSA) Stock Is Skyrocketing

Baird Maintains Outperform on Arrowhead Pharma, Lowers Price Target to $58